Tyk2

Pfizer sells midphase inflammatory drugs to mystery startup, exiting race against Bristol Myers
Fierce Biotech
Tue, 11/2/21 - 11:55 pm
Pfizer
Tyk2
deucravacitinib
Bristol Myers Squibb
Six burning Otezla questions
EP Vantage
Tue, 08/27/19 - 10:53 pm
Celgene
Otezla
Amgen
drug pricing
FTC
Tyk2
Bristol-Myers Squibb